Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Company Deals

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Fineline Cube Apr 10, 2026
Company Deals

Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer

Fineline Cube Apr 10, 2026
Company Deals

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Fineline Cube Apr 10, 2026
Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Fineline Cube Apr 10, 2026
Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Fineline Cube Apr 10, 2026
Company Deals

Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million

Fineline Cube Jun 20, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of...

Company

Jiuzhou Pharmaceutical Shuts Down Two Subsidiaries to Streamline Operations

Fineline Cube Jun 20, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a pharmaceutical company based in China, has announced...

Company Drug

Keymed Biosciences’ CM313 Shows Promise in Treating Immune Thrombocytopenia, NEJM Study Says

Fineline Cube Jun 20, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has published results from...

Company Deals

Xencor Reclaims Rights to Plamotamab After Janssen Halts Development

Fineline Cube Jun 20, 2024

Xencor Inc. (NASDAQ: XNCR), a U.S.-based biotechnology company, has announced that Johnson & Johnson (J&J,...

Company Drug

AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio

Fineline Cube Jun 20, 2024

AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...

Company Deals

Genrix Biopharmaceutical and Chongqing Pharmaceutical Group Form Strategic Partnership to Boost Market Launch

Fineline Cube Jun 20, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a biopharmaceutical company based in China, has entered...

Company

AstraZeneca’s Gracell Biotechnologies to Expand Cell Therapy Manufacturing in China

Fineline Cube Jun 20, 2024

Gracell Biotechnologies, a China-based cell therapy specialist owned by AstraZeneca (AZ; NASDAQ: AZN), is reportedly...

Company Drug

NMPA Releases 81st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jun 19, 2024

The National Medical Products Administration (NMPA) has released the 81st batch of reference drugs for...

Company Deals

Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion

Fineline Cube Jun 19, 2024

Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has...

Company Deals

3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion

Fineline Cube Jun 19, 2024

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term...

Company Medical Device

Hybribio Ltd Secures NMPA Approval for α-Thalassemia Genotyping Detection Kit

Fineline Cube Jun 19, 2024

Hybribio Ltd (SHE: 300639), a Guangdong-based provider of nucleic acid molecular diagnostic products, has announced...

Company Drug

Kanghong Pharmaceutical’s Lumitin Approved in Myanmar for Neovascular AMD Treatment

Fineline Cube Jun 19, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...

Company Drug

Suzhou Zelgen’s Recombinant Human Thyroid Stimulating Hormone Accepted for NMPA Review

Fineline Cube Jun 19, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

Sanofi Partners with Belharra Therapeutics to Tap into Chemoproteomics for Immunology Targets

Fineline Cube Jun 19, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), a major French pharmaceutical company, has formed a collaboration with...

Company Drug

Clover Biopharmaceuticals’ RSV Vaccine Candidate Shows Promising Results in Elderly

Fineline Cube Jun 19, 2024

Clover Biopharmaceuticals Ltd. (HKG: 2197), a biopharmaceutical company based in China, has announced positive preliminary...

Company Deals

Day One Biopharmaceuticals Expands Pipeline with MabCare Therapeutics Licensing Deal

Fineline Cube Jun 19, 2024

Day One Biopharmaceuticals (NASDAQ: DAWN), a California-based biotech company that recently celebrated its first drug...

Company Drug

China Medical System’s Methylthioninium Tablets Get NMPA Green Light for Colonoscopy Use

Fineline Cube Jun 19, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received New Drug...

Company Drug

AstraZeneca’s AKT Inhibitor Truqap Misses Primary Endpoints in Phase III TNBC Trial

Fineline Cube Jun 19, 2024

AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has encountered a setback in the Phase...

Company Drug

MSD’s Capvaxive Vaccine Targets 21 Serotypes of Streptococcus Pneumoniae

Fineline Cube Jun 19, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced...

Company Deals

Roche Secures RNA Exon Editing Tech for Neurological Diseases with Ascidian Deal

Fineline Cube Jun 19, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY), a Swiss pharmaceutical giant, is expanding its footprint in the...

Posts pagination

1 … 325 326 327 … 648

Recent updates

  • C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology
  • Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis
  • Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K
  • Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia
  • BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Company Deals

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.